CME: Precision Oncology: Incorporating Next Generation Sequencing (NGS) in NSCLC

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Precision Oncology: Incorporating Next Generation Sequencing (NGS) in NSCLC

Program Information
Precision Oncology:  Incorporating Next Generation Sequencing (NGS) in NSCLC
Oncology experts discuss how next-generation sequencing can help oncologists and pathologists make personalized treatment decisions.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Non-small cell lung cancer (NSCLC) is a leading cause of cancer death in the United States.  Identification of targetable mutations has led to the development of therapies and improvements in NSCLC patient outcomes.  However, many patients continue to experience poor survival due to suboptimal genomic profiling and treatment.  In this activity, we will evaluate the advantages of NGS testing platforms and companion diagnostics over the conventional genomic profiling approach and discuss strategies to overcome barriers to wide adoption in community oncology settings.

    Dr. Joshua Bauml is joined by Dr. Timothy McCarthy to discuss incorporating NGS in NSCLC. 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Joshua M. Bauml, MD
    Assistant Professor of Medicine
    Perelman School of Medicine at University of Pennsylvania
    Philadelphia, PA

    Dr. Bauml receives consulting fees from AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech, Inc; Guardant Health; Merck; and Takeda; and conducts contracted research from AstraZeneca; Janssen Pharmaceuticals, Inc; Merck; Novartis; and Takeda.

    Timothy A. McCarthy, MD
    Medical Oncology/Hematology
    Virginia Cancer Specialists
    Fairfax, VA

    Dr. McCarthy has no financial relationships to report.


    • Carole Drexel, PhD, CHCP, has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Jessica McGrory has nothing to disclose.
    • Lawrence Sherman, FACEHP, CHCP, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Incorporate a management strategy to include companion diagnostics to ensure personalized treatment for patients with NSCLC in the community oncology setting.
    • Evaluate the advantages of FDA-approved NGS testing platforms over conventional genomic profiling approaches.
    • Discuss strategies to overcome difficulties in integrating NGS testing in NSCLC and effectively communicate with pathologists.
  • Target Audience

    This activity is designed to meet the educational needs of community-based medical oncologists, other oncologists, pathologists, and oncology nurses.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    AGILE - Academy for Interprofessional Learning and Education - designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions.  Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes.  

  • Commercial Support

    This activity is supported by an independent educational grant from Thermo Fisher Scientific, Clinical Sequencing Division.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of AGILE, you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio


Programs 9/21/19

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.